LAURUS LABS, once a leading manufacturer of antiretroviral (ARV) drugs, is undergoing yet another transformation under Satyanarayana Chava, its Founder & CEO. Until 2011, ARVS-a group of medication used to manage and treat human immunodeficiency virus (HIV) infection-accounted for a substantial portion of the company's revenue. Then it made a strategic shift towards becoming an active pharmaceutical ingredient (API)-focussed company.
Subsequently, the company forayed into the formulations business in 2014, which helped it become an integrated pharma company by 2020. As a result of that shift, the ARV API contributes only 25% of revenues now, while the contract development and manufacturing organisation (CDMO) segment has seen significant growth.
The success of these shifts is evident in the numbers. Over the past five years, Laurus Labs, which was founded in 2005, has seen a significant growth in revenues, rising from ₹2,292 crore in FY19 to ₹6,041 crore in FY23, an increase of 164% over the period. However, there has been a slight dip in revenues in the first nine months of FY24, settling at ₹3,601 crore.
Further, Laurus Labs's biotechnology business represents a strategic diversification into a high-growth sector with significant potential for development. The biotech business is relatively new, launched in 2021 through the acquisition of Richcore Life Sciences, a pioneer in microbial fermentation technology.
This story is from the March 17, 2024 edition of Business Today India.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber ? Sign In
This story is from the March 17, 2024 edition of Business Today India.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber? Sign In
"Attitude Decides Altitude"
BEST ADVICE - RAJNEET KOHLI, CEO & EXECUTIVE DIRECTOR, BRITANNIA INDUSTRIES LTD
"FOR RATAN TATA, IT WAS ALWAYS NATION FIRST"
Thomas Matthew, former IAS officer, on his new biography of Ratan Tata, the late Chairman Emeritus of Tata Sons
"RADICAL CHANGE NEEDED TO IMPROVE URBAN INFRA"
K.P. Singh, Chairman Emeritus of DLF, on the dynamic nature of the real estate sector, challenges in urban planning, and more
REDEFINING AMBITION
Shashikant Ruia was a visionary entrepreneur who navigated challenges with resilience. He leaves behind a rich legacy of ambition and leadership
ON THE WILD SIDE
LOVE WILDLIFE BUT DON'T WANT TO GIVE UP ON THE FINER THINGS WHILE ON A TRIP TO SPOT ANIMALS? CHECK OUT THESE LUXURIOUS WILDLIFE RESORTS FOR THE HOLIDAY SEASON
"India is the only market globally with substantial growth"
RHI Magnesita CEO Stefan Borgas on the company's M&A strategy, why India is important, the way ahead, and more
FRESH ON THE STREET
IPOs have come back with a bang in 2024, with a record ₹1.3 lakh crore raised till October. As a result, many newly-listed firms have made it to the BT500 list
RIDING THE WAVES
The shipping industry is on the brink of a transformation. Beyond government support and technological advancements, what are the other driving forces and emerging trends that will define the landscape in 2025?
HOME RUN
After a decade-long slowdown, India’s real estate market reached its highest decadal sales level in the first half of 2024
In Pursuit of Good Health
The past year has been eventful for the Indian pharma sector, with some companies witnessing growth, and some challenges. The outlook for the sector, however, remains positive
